|
|
("
Grant of Options
The exercise price for the Options is
Options granted to Executive Directors and employees
Upon the recommendation of the Company's remuneration committee, the Company has granted 4,875,000 of the Options to the Company's Executive Directors and certain other employees pursuant to the Company's Share Option Plan which was adopted on
Director |
Ordinary Shares under Option |
|
1,500,000 |
|
1,875,000* |
*includes 375,000 Options granted to
Messrs Dimitriou and Zimmer currently have the following interests in issued Ordinary Shares:
Director |
Number of Ordinary Shares |
% of issued share capital at |
|
3,567,430 |
2.69 |
|
25,344,514* |
19.12 |
*includes 792,961 shares held by
Following the grant of the options referred to above, Messrs Dimitriou and Zimmer will have the following interests in share options in the Company:
Director |
Number of options |
Exercise Price |
Expiry Date |
|
140,000 1,000,000 1,500,000 |
86.50p 50.25p 98.62p |
|
|
200,000* 50,000* 100,000* 1,250,000* 1,875,000* |
86.50p 90.75p 43.88p 50.25p 98.62p |
|
*includes options granted to
Following this grant of Options summarised above, the total number of share options outstanding pursuant to the 2017 Plan will be 8,125,000 representing 6.15% of
Options granted to Non-executive Directors
The Company has also granted certain Options to Non-executive Directors as summarised in the following table:
Director |
Ordinary Shares under Option |
|
1,500,000 |
|
300,000 |
|
300,000 |
Messrs McCarthy,
Director |
Number of Ordinary Shares |
% of issued share capital at |
|
38,462 |
0.03% |
|
99,412 |
0.08% |
|
21,490 |
0.02% |
Following the grant of the Options referred to above, Messrs McCarthy,
Director |
Number of Ordinary Shares under Option |
Exercise Price |
Expiry Date |
|
500,000 1,000,000 1,500,000 |
43.88p 56.75p 98.62p |
|
|
100,000 100,000 200,000 300,000 |
86.50p 43.88p 56.75p 98.62p |
|
|
100,000 200,000 300,000 |
43.88p 56.75p 98.62p |
|
Total Share Options
As stated above, the total options outstanding under both the 2017 Plan and the Company's previous share option plan is 10,130,000, representing 7.64% of
This announcement contains inside information for the purpose of Article 7 of Regulation (EU) 596/2014.
Ends
For further information, please contact:
|
|
Twitter: @immupharma
|
+44 (0) 20 7152 4080 +44 (0) 7721 413496 |
|
+44 (0) 20 3861 6625 |
This information is provided by RNS